H L Bradlow
Overview
Explore the profile of H L Bradlow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
249
Citations
2379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Telang N, Li G, Sepkovic D, Bradlow H, Wong G
Mol Med Rep
. 2011 Oct;
5(1):22-8.
PMID: 21971582
Selective estrogen receptor modulators and a combination of mechanistically distinct chemotherapeutic agents represent conventional therapeutic interventions for estrogen receptor-positive (ER+) clinical breast cancer. Long-term treatment with these agents is associated...
2.
Bradlow H, ZELIGS M
In Vivo
. 2010 Jul;
24(4):387-91.
PMID: 20668304
Unlabelled: Indole-3-carbinol (I3C) when given orally is converted to diindolylmethane (DIM) and other oligomers catalyzed by stomach acid. This suggests that DIM is the predominant active agent and that I3C...
3.
Bradlow H, VANDERWERF C
J Am Chem Soc
. 2010 Mar;
69(3):662-4.
PMID: 20289452
No abstract available.
4.
Alvarez-Vasquez R, Axelrod D, Frenkel K, Newman M, Sepkovic D, Bradlow H, et al.
Horm Metab Res
. 2003 Aug;
35(6):358-61.
PMID: 12920658
Whether postmenopausal hormone-replacement therapy (HRT) increases the risk of breast cancer remains controversial, despite numerous epidemiological studies. We approached the question from a biochemical rather than an epidemiological direction -...
5.
Jernstrom H, Klug T, Sepkovic D, Bradlow H, Narod S
Carcinogenesis
. 2003 May;
24(5):991-1005.
PMID: 12771045
Studies of circulating estrogen levels in relation to pre-menopausal breast cancer risk have yielded inconsistent results. Various estrogen metabolites might affect the risk differently. Estradiol metabolism occurs primarily via two...
6.
Sepkovic D, Bradlow H, Bell M
Nutr Cancer
. 2002 Jul;
41(1-2):57-63.
PMID: 12094629
Indole-3-carbinol (I3C) or, more correctly, its acid condensation products act as chemoprotective agents via several mechanisms. It induces the expression of cytochrome P-450 1A1, which shifts the estrogen metabolic pathway...
7.
Ashok B, Chen Y, Liu X, Bradlow H, Mittelman A, Tiwari R
Nutr Cancer
. 2002 Jul;
41(1-2):180-7.
PMID: 12094623
The use of naturally occurring phytoantiestrogens for prevention and therapy of breast cancer is an alternative to synthetic antiestrogens. We have been examining the mechanism of action of the antiestrogen...
8.
BYRNE J, Bradlow H
Diabetes Technol Ther
. 2001 Aug;
3(2):211-9.
PMID: 11478327
The etiology of non-insulin-dependent diabetes mellitus (NIDDM) is complex and development is manifested by initial insulin resistance coupled with elevated insulin levels in the early diabetic state with concomitant increases...
9.
Riza E, dos Santos Silva I, De Stavola B, Bradlow H, Sepkovic D, Linos D, et al.
Cancer Epidemiol Biomarkers Prev
. 2001 Jun;
10(6):627-34.
PMID: 11401912
It has been hypothesized that women who metabolize their endogenous estrogens predominantly via 16(alpha)-hydroxylation rather than via 2-hydroxylation and, as a result, have a low ratio of 2-hydroxyestrone (2-OHE1):16(alpha)-hydroxyestrone (16(alpha)-OHE1)...
10.
Weyant M, Carothers A, Mahmoud N, Bradlow H, Remotti H, Bilinski R, et al.
Cancer Res
. 2001 Apr;
61(6):2547-51.
PMID: 11289129
Menopausal hormone replacement therapy has been widely used to alleviate the symptoms of menopause and to decrease the detrimental effects of ovarian hormone loss on bone density and cardiovascular health....